In similar studies conducted by Scotti et al, combining G129R-hPRL with Herceptin resulted in suppression of STAT3 and STAT5 phosphorylation and reduced HER2 expression in T47D and BT474 breast cancer cells (54). The gene discussed is ERBB2; the disease is breast carcinoma.